Arcus Biosciences Announces New Employment Inducement Grants

Arcus Biosciences, Inc. (NYSE:RCUS), a clinical-stage, global biopharmaceutical company focused on developing differentiated molecules and combination therapies for patients with cancer, today announced that the Compensation Committee of the Company's Board of Directors granted twelve new employees options to purchase a total of 42,920 shares of the Company's common stock at an exercise price per share of $9.12, which was the closing price on March 24, 2025, and restricted stock units to acquire a total of 21,650 shares of the Company's common stock. The equity awards were granted pursuant to the Company's 2020 Inducement Plan, which was approved by the Company's Board of Directors in Janua

Arcus Biosciences (NYSE:RCUS), a clinical-stage, global biopharmaceutical company focused on developing differentiated molecules and combination therapies for patients with cancer, announced that its management team will participate in the following upcoming investor conferences in March: Leerink Global Healthcare Conference 2025 Date: Wednesday, March 12th, 2025 Location: Miami Beach, FL Format: Fireside chat & 1x1 meetings Time: 8:00 a.m. ET Barclays 27th Annual Global Healthcare Conference Date: Thursday, March 13th, 2025 Location: Miami Beach, FL Format: Fireside chat & 1x1 meetings Time: 8:00 a.m. ET Live webcasts of the fireside chats and panel will be available by visiting the

New data from the Phase 1/1b ARC-20 study showed that casdatifan improved upon the rate of primary progression, overall response rate (ORR) and progression-free survival (PFS) relative to published data from studies with HIF-2a inhibitors to date Initiation of the Phase 3 study for PEAK-1 evaluating casdatifan in combination with cabozantinib versus cabozantinib in immuno-oncology (IO)-experienced patients with clear cell renal cell carcinoma (ccRCC) is expected in the first half of 2025; initial data from the cohort of ARC-20 evaluating casdatifan plus cabozantinib are expected to be presented in mid-2025 Arcus completed a $150 million financing and continues to be well positioned

H.C. Wainwright upgraded Arcus Biosciences from Neutral to Buy and set a new price target of $24.00 from $18.00 previously

H.C. Wainwright initiated coverage of Arcus Biosciences with a rating of Neutral and set a new price target of $20.00

Wells Fargo initiated coverage of Arcus Biosciences with a rating of Overweight and set a new price target of $29.00

4 - Arcus Biosciences, Inc. (0001724521) (Issuer)

4 - Arcus Biosciences, Inc. (0001724521) (Issuer)

4 - Arcus Biosciences, Inc. (0001724521) (Issuer)

4 - Arcus Biosciences, Inc. (0001724521) (Issuer)

4 - Arcus Biosciences, Inc. (0001724521) (Issuer)

4 - Arcus Biosciences, Inc. (0001724521) (Issuer)

SCHEDULE 13D/A - Arcus Biosciences, Inc. (0001724521) (Subject)

S-8 - Arcus Biosciences, Inc. (0001724521) (Filer)

10-K - Arcus Biosciences, Inc. (0001724521) (Filer)

Arcus Biosciences, Inc. (NYSE:RCUS), a clinical-stage, global biopharmaceutical company focused on developing differentiated molecules and combination therapies for patients with cancer, today announced that, in connection with the appointment of the Company's new Chief Medical Officer, Richard Markus, M.D., Ph.D., the Compensation Committee of the Company's Board of Directors granted Dr. Markus an option to purchase 305,328 shares of the Company's common stock at an exercise price per share of $12.45, which was the closing price on February 10, 2025, and restricted stock units to acquire a total of 75,193 shares of the Company's common stock. In addition to the awards to Dr. Markus, the Co

Dr. Markus will oversee Arcus's clinical development organization and portfolio that includes seven clinical-stage programs with multiple ongoing Phase 3 studies   Arcus Biosciences, Inc. (NYSE:RCUS), a clinical-stage, global biopharmaceutical company focused on developing differentiated molecules and combination therapies for people with cancer, today announced that Richard Markus, M.D., Ph.D., has been appointed chief medical officer (CMO) effective January 31, 2025. Dr. Markus replaces Dimitry Nuyten, M.D., Ph.D., who will be leaving the company at the end of January to pursue other opportunities. Dr. Markus's responsibilities will include oversight of Arcus's clinical development

Arcus Biosciences, Inc. (NYSE:RCUS), an oncology-focused biopharmaceutical company working to create best-in-class cancer therapies, today announced that, in connection with the appointment of the Company's new Chief Medical Officer, Dimitry S.A. Nuyten, M.D., Ph.D, the Compensation Committee of the Company's Board of Directors granted Dr. Nuyten an option to purchase 170,000 shares of the Company's common stock at an exercise price per share of $26.00, which was the closing price on August 23, 2022, and restricted stock units to acquire a total of 42,500 shares of the Company's common stock. In addition to the awards to Dr. Nuyten, the Compensation Committee granted fifteen other new emplo

A 9.7-month median progression-free survival (mPFS) was reached for the 50mg twice-daily (BID) casdatifan monotherapy cohort of the Phase 1/1b ARC-20 study; mPFS was not yet reached for other cohorts Across all three monotherapy cohorts presented, casdatifan demonstrated improvements in the rate of primary progression, overall response rate (ORR) and progression-free survival (PFS) relative to published data from studies with HIF-2a inhibitors to date Arcus will host a conference call to discuss these data at 5:00 AM PT / 8:00 AM ET on Tuesday, February 18, 2025 Arcus Biosciences, Inc. (NYSE:RCUS), a clinical-stage, global biopharmaceutical company focused on developing differentiate

New data from ARC-20, a Phase 1/1b study of the HIF-2a inhibitor casdatifan in clear cell renal cell carcinoma (ccRCC), will be presented in a rapid oral session by Dr. Toni Choueiri, Dana-Farber Cancer Institute The presentation will include initial data from the 100mg once-daily (QD) tablet cohort and updated data for the 50mg twice-daily (BID) and 50mg QD cohorts Arcus will host a conference call to discuss the ARC-20 data at 5:00 AM PT / 8:00 AM ET on Tuesday, February 18, 2025 Arcus Biosciences, Inc. (NYSE:RCUS), a clinical-stage, global biopharmaceutical company focused on developing differentiated molecules and combination therapies for patients with cancer, today announc

Data from the Phase 1/1b ARC-20 study of casdatifan were presented at an oral plenary session at the 2024 EORTC-NCI-AACR Symposium; a low rate of primary progression (19%) and promising objective response rate (34% with 2 responses pending confirmation, 25% confirmed) for the 100mg daily (50mg twice-daily) cohort of heavily pretreated patients with clear-cell renal cell carcinoma (ccRCC) support a potential best-in-class profile Arcus announced a clinical trial collaboration agreement with AstraZeneca to evaluate casdatifan in combination with volrustomig, an investigational PD-1/CTLA-4 bispecific antibody, in patients with immuno-oncology (IO)-naive ccRCC Data from the randomized ARC-

SC 13D/A - Arcus Biosciences, Inc. (0001724521) (Subject)

SC 13G/A - Arcus Biosciences, Inc. (0001724521) (Subject)

SC 13G/A - Arcus Biosciences, Inc. (0001724521) (Subject)